SCHEMBL5452097

SCHEMBL5452097

CCOc1ccc(-c2ccc(C3(O)CCN(C(=O)OCC(=O)NC)CC3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
PKM P14618 2/20 0.42
FAAH O00519 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HRH2 P25021 8/20 0.42
HRH1 P35367 8/20 0.42
TET3 O43151 1/20 0.42
KMT2A Q03164 1/20 0.42
FBXL19 Q6PCT2 1/20 0.42
CXXC5 Q7LFL8 1/20 0.42
TET1 Q8NFU7 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
CXXC4 Q9H2H0 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
HTT P42858 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447927 0.89 SMN1; SMN2 (0.45) LMNAMAPTSMN1; SMN2PKMFAAH
SCHEMBL5445764 0.87 FAAH (0.45) LMNASMN1; SMN2FAAHL3MBTL1KMT2A
SCHEMBL5442739 0.86 FAAH (0.57) SMN1; SMN2FAAHHRH2HRH1KMT2A
SCHEMBL5453462 0.86 SMN1; SMN2 (0.46) LMNASMN1; SMN2FAAH
SCHEMBL5452293 0.83 FAAH (0.50) SMN1; SMN2FAAHL3MBTL1HRH1ALDH1A1
SCHEMBL5447955 0.83 FAAH (0.44) SMN1; SMN2FAAHHRH2HRH1HRH3
SCHEMBL5443508 0.82 FAAH (0.46) MAPTSMN1; SMN2FAAHL3MBTL1HRH2
SCHEMBL5442748 0.82 FAAH (0.47) LMNAMAPTSMN1; SMN2FAAHL3MBTL1
SCHEMBL5239162 0.81 MAPT (0.53) GAALMNAMAPTSMN1; SMN2PKM
SCHEMBL1581964 0.81 KMT2A (0.52) GAALMNASMN1; SMN2L3MBTL1TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021405-A1 ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021405-A1 ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, HRH2 GAA 716/4885LMNA 2014/4885MAPT 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.